Small Entity Compliance Guide: Bottled Water: Total Coliform and E. coli, 14607-14608 [2010-6699]
Download as PDF
Federal Register / Vol. 75, No. 58 / Friday, March 26, 2010 / Notices
II. Criteria for Nominees
The Panel must be fairly balanced in
its membership in terms of the points of
view represented and the functions to
be performed. The Panel shall consist of
up to 15 members who are
representatives of providers. Each Panel
member must be employed full-time by
a hospital, hospital system, or other
Medicare provider subject to payment
under the OPPS. All members must
have technical expertise to enable them
to participate fully in the Panel’s work.
Such expertise encompasses hospital
payment systems; hospital medical care
delivery systems; provider billing
systems; APC groups; Current
Procedural Terminology codes; and
alpha-numeric Health Care Common
Procedure Coding System codes; and
the use of, and payment for, drugs and
medical devices, as well as other forms
of relevant expertise.
It is not necessary for a nominee to
possess expertise in all of the areas
listed, but each must have a minimum
of 5 years experience and currently have
full-time employment in his or her area
of expertise. Generally, members of the
Panel serve overlapping terms of 4
years, based on the needs of the Panel
and contingent upon the re-chartering of
the Panel.
Any interested person or organization
may nominate one or more qualified
individuals. Self-nominations will also
be accepted. Each nomination must
include the following:
• Letter of Nomination,
• Curriculum Vitae of the nominee,
and
• Written statement from the nominee
that the nominee is willing to serve on
the Panel under the conditions
described in this notice and further
specified in the Charter.
emcdonald on DSK2BSOYB1PROD with NOTICES
III. Copies of the Charter
To obtain a copy of the Panel’s
Charter, submit a written request to the
DFO at the address provided in the
ADDRESSES section or by e-mail at CMS
APCPanel@cms.hhs.gov, or call 410–
786–4474.
Copies of the Charter are also
available on the Internet at the
following: https://www.cms.hhs.gov/
FACA/05_
AdvisoryPanelonAmbulatoryPayment
ClassificationGroups.asp#TopOfPage.
IV. Collection of Information
Requirements
This document does not impose
information collection and
recordkeeping requirements.
Consequently, it need not be reviewed
by the Office of Management and
VerDate Nov<24>2008
15:23 Mar 25, 2010
Jkt 220001
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 35).
(Catalog of Federal Domestic Assistance
Program No. 93.774, Medicare—
Supplementary Medical Insurance Program)
Dated: March 18, 2010.
Charlene Frizzera,
Acting Administrator, Centers for Medicare
& Medicaid Services.
[FR Doc. 2010–6789 Filed 3–25–10; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–D–0141]
Small Entity Compliance Guide:
Bottled Water: Total Coliform and E.
coli; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘Bottled Water: Total Coliform
and E. coli—Small Entity Compliance
Guide’’ for a final rule published in the
Federal Register of May 29, 2009. This
small entity compliance guide (SECG) is
intended to set forth in plain language
the requirements of the regulation and
to help small businesses understand the
regulation.
DATES: Submit electronic or written
comments on the SECG at any time.
ADDRESSES: Submit electronic
comments on the SECG to https://
www.regulations.gov. Submit written
comments on the SECG to the Division
of Dockets Management (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD
20852. Submit written requests for
single copies of the SECG to the
Division of Plant and Dairy Food Safety
(HFS–317), Office of Food Safety, Center
for Food Safety and Applied Nutrition,
Food and Drug Administration, 5100
Paint Branch Pkwy., College Park, MD
20740, or fax your request to 301–436–
2651. Send one self-addressed adhesive
label to assist that office in processing
your request. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the SECG.
FOR FURTHER INFORMATION CONTACT:
Lauren Posnick Robin, Center for Food
Safety and Applied Nutrition (HFS–
317), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park,
MD 20740, 301–436–1639.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
14607
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of May 29,
2009 (74 FR 25651), FDA issued a final
rule amending its bottled water
regulations to require that bottled water
manufacturers test source water for total
coliform, as is required for finished
bottled water products, and to require,
if any coliform organisms are detected
in source water, that bottled water
manufacturers determine whether any
of the coliform organisms are
Escherichia coli (E. coli), an indicator of
fecal contamination. FDA also amended
its bottled water regulations to require,
if any coliform organisms are detected
in finished bottled water products, that
bottled water manufacturers determine
whether any of the coliform organisms
are E. coli. FDA also amended the
adulteration provision of the bottled
water standard to reflect the possibility
of adulteration caused by the presence
of filth. Under the amended regulations,
bottled water containing E. coli will be
considered adulterated, and source
water containing E. coli will not be
considered to be of a safe, sanitary
quality and will be prohibited from use
in the production of bottled water. FDA
also amended its bottled water
regulations to require that, before a
bottler can use source water from a
source that has tested positive for E.
coli, the bottler must take appropriate
measures to rectify or eliminate the
cause of E. coli contamination of that
source, and that the bottler must keep
records of such actions. Existing
regulatory provisions require bottled
water manufacturers to keep records of
new testing required by this rule. The
effective date of the final rule is
December 1, 2009.
FDA examined the economic
implications of the final rule as required
by the Regulatory Flexibility Act (5
U.S.C. 601–612). Because the costs per
entity of this rule are small, the agency
believes that the final rule will not have
a significant economic impact on a
substantial number of small entities.
However, FDA could not certify that the
final rule would not have a significant
economic impact on a substantial
number of small entities. Therefore, in
compliance with section 212 of the
Small Business Regulatory Enforcement
Fairness Act (Public Law 104–121), FDA
is making available this SECG stating in
plain language the legal requirements of
the May 29, 2009, final rule set forth in
21 CFR parts 129 and 165 concerning
the monitoring requirements for total
coliform and E. coli in source water and
finished bottled water products, the
allowable levels of total coliform and E.
E:\FR\FM\26MRN1.SGM
26MRN1
14608
Federal Register / Vol. 75, No. 58 / Friday, March 26, 2010 / Notices
coli in finished bottled water products,
and requirements for recordkeeping and
corrective measures.
FDA is issuing this SECG as level 2
guidance consistent with FDA’s good
guidance practices regulation (21 CFR
10.115(c)(2)). The SECG represents the
agency’s current thinking on this topic.
It does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) electronic or written
comments regarding this SECG. Submit
a single copy of electronic comments or
two paper copies of any mailed
comments, except that individuals may
submit one paper copy. Comments are
to be identified with the docket number
found in brackets in the heading of this
document. The SECG and received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
§ 129.35(a)(3)(i) and § 129.80(g) and (h)
have been approved under OMB control
no. 0910–0658.
IV. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/FoodGuidances or https://
www.regulations.gov.
Dated: March 22, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–6699 Filed 3–25–10; 8:45 am]
BILLING CODE 4160–01–S
emcdonald on DSK2BSOYB1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
VerDate Nov<24>2008
15:23 Mar 25, 2010
Jkt 220001
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 75 FR 10296, dated
March 5, 2010) is amended to reflect the
reorganization of the Office of the Chief
Science Officer, Office of the Director,
Centers for Disease Control and
Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows: Delete in its entirety the title
and functional statement for the Office
of the Chief Science Officer (CAS), and
insert the following:
Office of the Associate Director for
Science (CAS). The Associate Director
for Science (OADS) and staff provide
CDC/ATSDR with scientific vision and
leadership in promoting quality and
integrity of CDC science, and helping to
encourage the application of science to
solving important public health
problems.
Office of the Director (CAS1). (1)
Directs, manages, and coordinates the
activities of the OADS; (2) develops
goals and objectives, provides
leadership, policy formation, scientific
oversight, and guidance in program
planning and development; and (3)
oversees functions of Office of Science
Quality and Translation, Office of
Scientific Integrity, and Innovation and
Special Projects Activity.
Innovation and Special Projects
Activity (CAS13). (1) Provides oversight
and leadership in major or cross-cutting
scientific activities; (2) represents the
agency and the director on high-level
internal and external scientific activities
and groups; (3) develops and advances
CDC research priorities; (4) handles
high-profile or controversial issues and
mediates (internally and externally) in
difficult, contentious situations; (5)
helps to develop and encourage
innovation throughout the spectrum
from scientific discovery to the
application of science to solving health
problems; (6) maintains regular, open,
and transparent communication with
CDC science community and uses the
results to contribute to problem solving;
(7) provides oversight for CDC sciencerelated workgroups; (8) provides
leadership opportunities for scientists;
and (9) encourages appropriate internal
and external collaborations and
partnerships related to science issues.
Office of Science Quality and
Translation (CASH). (1) Provides
consultation and advice and support to
the CDC OD, National Centers,
programs, ADSs, MMWR, and other
relevant organizations related to
intramural and extramural scientific
PO 00000
Frm 00054
Fmt 4703
Sfmt 9990
activities; (2) leads development of
policies related to intramural and
extramural science; (3) performs and
facilitates good quality internal and
external peer review; (4) ensures
transparency and accountability of CDC
extramural research programs; (5)
provides oversight of knowledge
management activities involving
Documentum and eClearance; (6)
supports and champions evidence-based
decisionmaking to support practice,
program, and policy inside and outside
of CDC; (7) encourages the production
and communication of science products
that address essential questions for
practice and policy; (8) assures that
science products are perceived as timely
and useful for decisionmaking; (9)
enhances access to CDC publications;
(10) feeds back key program and policy
research gaps into the research agenda;
and (11) links the needs of public health
practitioners and decisionmakers into
the development of CDC research
projects and publications (in
collaboration with Associate Directors
for Program, and State, Tribal, Local,
and Territorial Support).
Office of Scientific Integrity (CASJ).
(1) Protects the rights and welfare of
human beings who participate in
research; (2) complies with laws and
principles in the care and use of
laboratory animals at CDC; (3) ensures
compliance with Paperwork Reduction
Act to protect the privacy of individuals
in records maintenance; (4) serves as the
agency research integrity liaison officer;
(5) ensures leadership in public health
ethics and integrate ethical analysis into
day-to-day decisions and activities
across CDC; (6) oversees emergency use
authorization (EUA); (7) establishes
newly required oversight and regulatory
activities; (8) provides independent
assessment and resolution of
contentious situations/issues; and (9)
provides training relevant to science
quality and integrity to CDC
community.
Dated: March 11, 2010.
William P. Nichols,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2010–6594 Filed 3–25–10; 8:45 am]
BILLING CODE 4160–18–M
E:\FR\FM\26MRN1.SGM
26MRN1
Agencies
[Federal Register Volume 75, Number 58 (Friday, March 26, 2010)]
[Notices]
[Pages 14607-14608]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-6699]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-D-0141]
Small Entity Compliance Guide: Bottled Water: Total Coliform and
E. coli; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry entitled ``Bottled Water: Total
Coliform and E. coli--Small Entity Compliance Guide'' for a final rule
published in the Federal Register of May 29, 2009. This small entity
compliance guide (SECG) is intended to set forth in plain language the
requirements of the regulation and to help small businesses understand
the regulation.
DATES: Submit electronic or written comments on the SECG at any time.
ADDRESSES: Submit electronic comments on the SECG to https://www.regulations.gov. Submit written comments on the SECG to the
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit written
requests for single copies of the SECG to the Division of Plant and
Dairy Food Safety (HFS-317), Office of Food Safety, Center for Food
Safety and Applied Nutrition, Food and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740, or fax your request to 301-436-
2651. Send one self-addressed adhesive label to assist that office in
processing your request. See the SUPPLEMENTARY INFORMATION section for
electronic access to the SECG.
FOR FURTHER INFORMATION CONTACT: Lauren Posnick Robin, Center for Food
Safety and Applied Nutrition (HFS-317), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1639.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of May 29, 2009 (74 FR 25651), FDA issued a
final rule amending its bottled water regulations to require that
bottled water manufacturers test source water for total coliform, as is
required for finished bottled water products, and to require, if any
coliform organisms are detected in source water, that bottled water
manufacturers determine whether any of the coliform organisms are
Escherichia coli (E. coli), an indicator of fecal contamination. FDA
also amended its bottled water regulations to require, if any coliform
organisms are detected in finished bottled water products, that bottled
water manufacturers determine whether any of the coliform organisms are
E. coli. FDA also amended the adulteration provision of the bottled
water standard to reflect the possibility of adulteration caused by the
presence of filth. Under the amended regulations, bottled water
containing E. coli will be considered adulterated, and source water
containing E. coli will not be considered to be of a safe, sanitary
quality and will be prohibited from use in the production of bottled
water. FDA also amended its bottled water regulations to require that,
before a bottler can use source water from a source that has tested
positive for E. coli, the bottler must take appropriate measures to
rectify or eliminate the cause of E. coli contamination of that source,
and that the bottler must keep records of such actions. Existing
regulatory provisions require bottled water manufacturers to keep
records of new testing required by this rule. The effective date of the
final rule is December 1, 2009.
FDA examined the economic implications of the final rule as
required by the Regulatory Flexibility Act (5 U.S.C. 601-612). Because
the costs per entity of this rule are small, the agency believes that
the final rule will not have a significant economic impact on a
substantial number of small entities. However, FDA could not certify
that the final rule would not have a significant economic impact on a
substantial number of small entities. Therefore, in compliance with
section 212 of the Small Business Regulatory Enforcement Fairness Act
(Public Law 104-121), FDA is making available this SECG stating in
plain language the legal requirements of the May 29, 2009, final rule
set forth in 21 CFR parts 129 and 165 concerning the monitoring
requirements for total coliform and E. coli in source water and
finished bottled water products, the allowable levels of total coliform
and E.
[[Page 14608]]
coli in finished bottled water products, and requirements for
recordkeeping and corrective measures.
FDA is issuing this SECG as level 2 guidance consistent with FDA's
good guidance practices regulation (21 CFR 10.115(c)(2)). The SECG
represents the agency's current thinking on this topic. It does not
create or confer any rights for or on any person and does not operate
to bind FDA or the public. An alternative approach may be used if such
approach satisfies the requirements of the applicable statutes and
regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) electronic or written comments regarding this SECG.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. The SECG and received comments may be
seen in the Division of Dockets Management between 9 a.m. and 4 p.m.,
Monday through Friday.
III. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in Sec. 129.35(a)(3)(i) and Sec. 129.80(g)
and (h) have been approved under OMB control no. 0910-0658.
IV. Electronic Access
Persons with access to the Internet may obtain the document at
https://www.fda.gov/FoodGuidances or https://www.regulations.gov.
Dated: March 22, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-6699 Filed 3-25-10; 8:45 am]
BILLING CODE 4160-01-S